ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTriple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by poor prognosis and limited therapeutic options. METTL3, a critical m6A RNA methyltransferase, has been implicated in tumor progression. However, its molecular mechanisms in TNBC remain to be fully elucidated.
methodsMETTL3 expression was analyzed using public databases, cell lines, and clinical samples. Functional assays were performed on TNBC cells following METTL3 knockdown or overexpression. RNA m6A levels were quantified to assess the methyltransferase activity of METTL3. MiR-338-5p was identified as a potential upstream regulator of METTL3 via prediction tools, and validated by luciferase assays. In vivo relevance was assessed using xenograft mouse models.
resultsMETTL3 was upregulated in TNBC cell lines and tumor tissues, correlating with larger tumor size and poorer prognosis. METTL3 knockdown suppressed proliferation, migration, invasion, and EMT, and reduced global RNA m6A modification. METTL3 overexpression enhanced these malignant traits and increased m6A levels. MiR-338-5p directly bound to the 3'UTR of METTL3 and suppressed METTL3 protein expression without affecting mRNA levels. Overexpression of miR-338-5p decreased RNA m6A levels and attenuated TNBC aggressiveness, effects that were reversed by METTL3 restoration, confirming a functional miR-338-5p/METTL3/m6A axis. In vivo, METTL3 overexpression promoted tumor growth and proliferation in xenograft models, whereas knockdown suppressed these effects.
conclusionMETTL3 functions as an oncogenic driver in TNBC by promoting proliferation, invasion, and EMT through an m6A-dependent mechanism. This study reveals post-transcriptional regulation of METTL3 by miR-338-5p in TNBC. Targeting this distinct regulatory axis represents a promising therapeutic strategy for TNBC.
Indexed as
Identifiers
42625113What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.